Over time, the continued use of photobiomodulation on the brain causes the brain to become a strengthened, upgraded organ as the cells begin to signal better and connectivity is repaired between the neurons. 

Current research has just scratched the surface as to advancing our understanding of how infrared light can be used to foster positive neurophysiological change. 

This is an exciting time for research, discovery in the field of digital neurotherapeutics, as it verges on discovering ever more profound answers and applications. We surely will gain greater understanding about the benefits of combining photobiomodulation and neurofeedback in remediating neuropsychiatric, neurodegenerative and neurodevelopmental disorders.

Below is a collection of the growing body of published research on clinical application of photobiomodulation.

 

Alzheimer's Disease

Photobiomodulation is showing to be a promising new treatment strategy for Alzheimer's and other forms of neurodegenerative conditions including amnestic mild cognitive impairment (aMCI). Along with demonstrated clinical effectiveness, it represents a safe, inexpensive, sustainable treatment in both the clinical and at-home setting.

Long COVID-19

Current evidence suggests how the impact of COVID can be mitigated by 1070nm photobiomodulation. Our current efforts are to obtain support for trials directed at the underlying pathophysiological response as well as clinical trials with long-COVID subjects. We intend to study how repeated exposure to the 1070nm PBM may decrease the duration and intensity of long-COVID cognitive and physical symptoms as well as diminish the severity of post infection neurological injury.

 

Parkinson's Disease

PBM has been successfully used in animal models to reduce the signs of Parkinson’s Disease and to protect dopaminergic neurons. Moreover, recent clinical trials have shown that photobiomodulation can be an effective treatment method for individuals diagnosed with Parkinson’s disease, as it has shown to improve measures of mobility, cognition, dynamic balance and fine motor skill.

 

Autism

The use of photobiomodulation on people with Autism is being widely studied as a new alternative option for aiding some of the symptoms of Autism. Each year more research is being conducted and trials facilitated to learn more about the application of photobiomodulation on people with Autism.

 

Healthy People - Optimal Performance

Photobiomodulation is not only something for those looking at alternative therapies. It can also be used on Healthy individuals to drive optimal performance, did you know Jack Dorsey used to stand under a near infrared light when working at Twitter?

 

Traumatic Brain Injury

Traumatic brain injury (TBI) is a brain dysfunction caused by some type of trauma to the head, often resulting from sports injuries, road traffic accidents,  or blast injuries suffered in military conflict.

Did you know that each year in America roughly 1.5 million people have Traumatic Brain Injury, with only 1 out of 6 being hospitalized?

 

Neuropsychiatric Conditions -Depression and Anxiety

Many animal and human studies have reported the beneficial effects from the application of near-infrared PBM to improve the psychological status of patients with major depression and anxiety. 

Studies reviewed and described below provide strong evidence that suggest the mechanism of PBM (increasing mitochondrial activity and energy production, increasing regional blood flow) has a downstream effect of not only ATP production, but also potentially increases intercellular signalling and connectivity.

According to Hopkins Medicine, 9.5% of adults over the age of 18 suffer from depressive illness each year.

 

Neuronic devices are not medical devices ​under any jurisdiction and are not intended to diagnose, treat, cure or prevent any disease. These statements have not been evaluated by the Food and Drug Administration. Neuronic is not providing any medical advice. We advise you to consult a medical professional and conduct your own independent research.